{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:36:56Z","timestamp":1773113816298,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The combination of taxanes and anthracyclines is still the mainstay of chemotherapy for early breast cancer. Capecitabine is an active drug with a favorable toxicity profile, showing strong anti-tumor activity against metastatic breast cancer. This trial assessed the efficacy and safety of the TX regimen (docetaxel and capecitabine) and compared it with the TE (docetaxel and epirubicin) regimen in locally advanced or high risk early HER2-negative breast cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>This randomized clinical trial was conducted at five academic centers in China. Eligible female patients were randomly assigned (1:1) to the TX (docetaxel 75\u00a0mg\/m<jats:sup>2<\/jats:sup> d1 plus capecitabine 1000\u00a0mg\/m<jats:sup>2<\/jats:sup> twice d1\u201314, q3w) or TE (docetaxel 75\u00a0mg\/m<jats:sup>2<\/jats:sup> d1 plus epirubicin 75\u00a0mg\/m<jats:sup>2<\/jats:sup> d1, q3w) groups for four cycles. The primary endpoint was a pathological complete response in the breast (pCR). Secondary endpoints included pCR in the breast and axilla, invasive disease-free survival (iDFS), overall survival (OS), and safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between September 1, 2012, and December 31, 2018, 113 HER2-negative patients were randomly assigned to the study groups (TX: <jats:italic>n<\/jats:italic>\u2009=\u200954; TE: <jats:italic>n<\/jats:italic>\u2009=\u200959). In the primary endpoint analysis, 14 patients in the TX group achieved a pCR, and nine patients in the TE group achieved a pCR (25.9% vs. 15.3%), with a not significant difference of 10.6% (95% CI -6.0\u201327.3%; <jats:italic>P<\/jats:italic>\u2009=\u20090.241). In a subgroup with high Ki-67 score, TX increased the pCR rate by 24.2% (95% CI 2.2\u201346.1%; <jats:italic>P<\/jats:italic>\u2009=\u20090.029). At the end of the 69-month median follow-up period, both groups had equivalent iDFS and OS rates. TX was associated with a higher incidence of hand-foot syndrome and less alopecia, with a manageable toxicity profile.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The anthracycline-free TX regimen yielded comparable pCR and long-term survival rates to the TE regimen. Thus, this anthracycline-free regimen could be considered in selected patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial Registration<\/jats:title>\n                <jats:p>ACTRN12613000206729 on 21\/02\/2013, retrospectively registered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10439-0","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T05:02:48Z","timestamp":1672203768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Houpu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopeng","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhicheng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuzhong","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingming","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaobin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,28]]},"reference":[{"key":"10439_CR1","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet Lond Engl. 2005;365:1687\u2013717.","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"10439_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2012","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. The Lancet. 2012;379:432\u201344.","journal-title":"The Lancet"},{"key":"10439_CR3","unstructured":"National Comprehensive Cancer Network. Breast cancer (version 6.2021). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 9 Sep 2021."},{"key":"10439_CR4","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","volume":"27","author":"S Jones","year":"2009","unstructured":"Jones S, Holmes FA, O\u2019Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol. 2009;27:1177\u201383.","journal-title":"J Clin Oncol"},{"key":"10439_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1200\/JCO.18.00028","volume":"37","author":"U Nitz","year":"2019","unstructured":"Nitz U, Gluz O, Clemens M, Malter W, Reimer T, Nuding B, et al. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J Clin Oncol. 2019;37:799\u2013808.","journal-title":"J Clin Oncol"},{"key":"10439_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1023\/A:1006497231579","volume":"18","author":"IH Capecitabine","year":"2000","unstructured":"Capecitabine IH. Preclinical Pharmacology Studies. Invest New Drugs. 2000;18:343\u201354.","journal-title":"Invest New Drugs"},{"key":"10439_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","volume":"40","author":"B Reigner","year":"2001","unstructured":"Reigner B, Blesch K, Weidekamm E. Clinical Pharmacokinetics of Capecitabine. Clin Pharmacokinet. 2001;40:85\u2013104.","journal-title":"Clin Pharmacokinet"},{"key":"10439_CR8","first-page":"1013","volume":"4","author":"N Sawada","year":"1998","unstructured":"Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol\/taxotere in human cancer xenografts. Clin Cancer Res Off J Am Assoc Cancer Res. 1998;4:1013\u20139.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10439_CR9","first-page":"945","volume":"7","author":"M Kurosumi","year":"2000","unstructured":"Kurosumi M, Tabei T, Suemasu K, Inoue K, Kusawake T, Sugamata N, et al. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep. 2000;7:945\u20138.","journal-title":"Oncol Rep"},{"key":"10439_CR10","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2007.15.8485","volume":"27","author":"S Chan","year":"2009","unstructured":"Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:1753\u201360.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10439_CR11","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","volume":"20","author":"J O\u2019Shaughnessy","year":"2002","unstructured":"O\u2019Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub J-P, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20:2812\u201323.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10439_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/annonc\/mdt410","volume":"25","author":"G von Minckwitz","year":"2014","unstructured":"von Minckwitz G, Rezai M, Fasching PA, Huober J, Tesch H, Bauerfeind I, et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40\u2014GeparQuattro). Ann Oncol. 2014;25:81\u20139.","journal-title":"Ann Oncol"},{"key":"10439_CR13","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1158\/1078-0432.CCR-15-0636","volume":"21","author":"J O\u2019Shaughnessy","year":"2015","unstructured":"O\u2019Shaughnessy J, Koeppen H, Xiao Y, Lackner MR, Paul D, Stokoe C, et al. Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clin Cancer Res. 2015;21:4305\u201311.","journal-title":"Clin Cancer Res"},{"key":"10439_CR14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/jamaoncol.2016.6120","volume":"3","author":"H Joensuu","year":"2017","unstructured":"Joensuu H, Kellokumpu-Lehtinen P-L, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, et al. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial. JAMA Oncol. 2017;3:793\u2013800.","journal-title":"JAMA Oncol"},{"key":"10439_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1200\/JCO.19.00904","volume":"38","author":"A Lluch","year":"2020","unstructured":"Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, et al. Phase III Trial of Adjuvant Capecitabine After Standard Neo-\/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM\/2003-11_CIBOMA\/2004-01). J Clin Oncol. 2020;38:203\u201313.","journal-title":"J Clin Oncol"},{"key":"10439_CR16","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1200\/JCO.19.00647","volume":"37","author":"HB Muss","year":"2019","unstructured":"Muss HB, Polley MYC, Berry DA, Liu H, Cirrincione CT, Theodoulou M, et al. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019;37:2338\u201348.","journal-title":"J Clin Oncol."},{"key":"10439_CR17","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017;376:2147\u201359.","journal-title":"N Engl J Med"},{"key":"10439_CR18","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1200\/JCO.19.02474","volume":"38","author":"J Li","year":"2020","unstructured":"Li J, Yu K, Pang D, Wang C, Jiang J, Yang S, et al. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38:1774\u201384.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10439_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","volume":"325","author":"X Wang","year":"2021","unstructured":"Wang X, Wang S-S, Huang H, Cai L, Zhao L, Peng R-J, et al. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. JAMA. 2021;325:50\u20138.","journal-title":"JAMA"},{"key":"10439_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053403","volume":"8","author":"Q Li","year":"2013","unstructured":"Li Q, Jiang Y, Wei W, Yang H, Liu J. Clinical Efficacy of Including Capecitabine in Neoadjuvant Chemotherapy for Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE. 2013;8: e53403.","journal-title":"PLoS ONE"},{"key":"10439_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2017.02.024","volume":"77","author":"A Natori","year":"2017","unstructured":"Natori A, Ethier J-L, Amir E, Cescon DW. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. Eur J Cancer. 2017;77:40\u20137.","journal-title":"Eur J Cancer"},{"key":"10439_CR22","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10549-007-9672-y","volume":"109","author":"KS Lee","year":"2008","unstructured":"Lee KS, Ro J, Nam B-H, Lee ES, Kwon Y, Kwon HS, et al. A randomized phase-III trial of docetaxel\/capecitabine versus doxorubicin\/cyclophosphamide as primary chemotherapy for patients with stage II\/III breast cancer. Breast Cancer Res Treat. 2008;109:481\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"10439_CR23","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1158\/1078-0432.CCR-04-2421","volume":"11","author":"R Rouzier","year":"2005","unstructured":"Rouzier R. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. Clin Cancer Res. 2005;11:5678\u201385.","journal-title":"Clin Cancer Res"},{"key":"10439_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1159\/000518573","volume":"44","author":"K Hong","year":"2021","unstructured":"Hong K, Yao L, Sheng X, Ye D, Guo Y. Neoadjuvant Therapy of Cyclin-Dependent Kinase 4\/6 Inhibitors Combined with Endocrine Therapy in HR+\/HER2\u2212 Breast Cancer: A Systematic Review and Meta-Analysis. Oncol Res Treat. 2021;44:557\u201367.","journal-title":"Oncol Res Treat"},{"key":"10439_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10549-018-4730-1","volume":"170","author":"R Chen","year":"2018","unstructured":"Chen R, Ye Y, Yang C, Peng Y, Zong B, Qu F, et al. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients. Breast Cancer Res Treat. 2018;170:35\u201343.","journal-title":"Breast Cancer Res Treat"},{"key":"10439_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009384","volume":"96","author":"M Tao","year":"2017","unstructured":"Tao M, Chen S, Zhang X, Zhou Q. Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis. Medicine (Baltimore). 2017;96: e9384.","journal-title":"Medicine (Baltimore)"},{"key":"10439_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5548252","volume":"2021","author":"M Pistelli","year":"2021","unstructured":"Pistelli M, Merloni F, Crocetti S, Scortichini L, Tassone L, Cantini L, et al. Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience. J Oncol. 2021;2021: e5548252.","journal-title":"J Oncol"},{"key":"10439_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10549-008-0081-7","volume":"116","author":"RL Jones","year":"2009","unstructured":"Jones RL, Salter J, A\u2019Hern R, Nerurkar A, Parton M, Reis-Filho JS, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009;116:53\u201368.","journal-title":"Breast Cancer Res Treat"},{"key":"10439_CR29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s005950200046","volume":"32","author":"T Kitabatake","year":"2002","unstructured":"Kitabatake T, Kojima K, Fukasawa M, Beppu T, Futagawa S. Correlation of Thymidine Phosphorylase Staining and the Ki-67 Labeling Index to Clinicopathologic Factors and Hepatic Metastasis in Patients with Colorectal Cancer. Surg Today. 2002;32:322\u20138.","journal-title":"Surg Today"},{"key":"10439_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/annonc\/mdn592","volume":"20","author":"C Andreetta","year":"2009","unstructured":"Andreetta C, Puppin C, Minisini A, Valent F, Pegolo E, Damante G, et al. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann Oncol. 2009;20:265\u201371.","journal-title":"Ann Oncol"},{"key":"10439_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.737849","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Wang Z, Fan S, Liu T, Yoshida S, Yang S, et al. Capecitabine Can Induce T Cell Apoptosis: A Potential Immunosuppressive Agent With Anti-Cancer Effect. Front Immunol. 2021;12: 737849.","journal-title":"Front Immunol"},{"key":"10439_CR32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747\u201352.","journal-title":"Nature"},{"key":"10439_CR33","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.annonc.2022.01.009","volume":"33","author":"CE Geyer","year":"2022","unstructured":"Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O\u2019Shaughnessy J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol. 2022;33:384\u201394.","journal-title":"Ann Oncol"},{"key":"10439_CR34","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382:810\u201321.","journal-title":"N Engl J Med"},{"key":"10439_CR35","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.3390\/cancers12061378","volume":"12","author":"A Gon\u00e7alves","year":"2020","unstructured":"Gon\u00e7alves A, Bertucci A, Bertucci F. PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond? Cancers. 2020;12:1378.","journal-title":"Cancers"},{"key":"10439_CR36","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.2001.19.3.602","volume":"19","author":"By the French Adjuvant Study Group","year":"2001","unstructured":"By the French Adjuvant Study Group. Benefit of a High-Dose Epirubicin Regimen in Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients With Poor Prognostic Factors: 5-Year Follow-Up Results of French Adjuvant Study Group 05 Randomized Trial. J Clin Oncol. 2001;19:602\u201311.","journal-title":"J Clin Oncol"},{"key":"10439_CR37","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10549-016-4075-6","volume":"161","author":"D Yamamoto","year":"2017","unstructured":"Yamamoto D, Sato N, Rai Y, Yamamoto Y, Saito M, Iwata H, et al. Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial. Breast Cancer Res Treat. 2017;161:473\u201382.","journal-title":"Breast Cancer Res Treat"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10439-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10439-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10439-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T09:07:48Z","timestamp":1672477668000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10439-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,28]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10439"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10439-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,28]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Peking University People\u2019s Hospital. Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1357"}}